Abstract
Inflammation seems to be at the beginning of the majority of chronic diseases, and major efforts are dedicated to the development of anti-inflammatory drugs. Chronic inflammatory diseases, such as psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and asthma, are diseases that affect a large segment of our population. Recent evidence suggests that even metabolic diseases, such as type 2 diabetes, and certain cardiovascular diseases, could also be considered to have an inflammatory origin. However, a chronic disorder that in its initial and even more advanced stages is often not life-threatening, presents a challenge for therapeutic intervention: companies have to develop drugs that are efficacious, relatively free of side effects, and can be used effectively for a long time. The identification of suitable targets, thus, depends on better understanding of the signaling pathways involved in the initiation and maintenance of inflammation. The availability of target validation technology, such as targeted mutagenesis in mice, gene silencing mediated by small interfering RNA and protein expression profiling in this context is of utmost importance. Here, we will focus on the latter two technologies.
Keywords: Mitogen Activated Protein (MAP) Kinases, Phosphoinositide 3-Kinases, Syk-Family Kinases, siRNA transfection, Protein Arrays
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling
Volume: 6 Issue: 1
Author(s): Tatjana Clarissa Gust and Arne v. Bonin
Affiliation:
Keywords: Mitogen Activated Protein (MAP) Kinases, Phosphoinositide 3-Kinases, Syk-Family Kinases, siRNA transfection, Protein Arrays
Abstract: Inflammation seems to be at the beginning of the majority of chronic diseases, and major efforts are dedicated to the development of anti-inflammatory drugs. Chronic inflammatory diseases, such as psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and asthma, are diseases that affect a large segment of our population. Recent evidence suggests that even metabolic diseases, such as type 2 diabetes, and certain cardiovascular diseases, could also be considered to have an inflammatory origin. However, a chronic disorder that in its initial and even more advanced stages is often not life-threatening, presents a challenge for therapeutic intervention: companies have to develop drugs that are efficacious, relatively free of side effects, and can be used effectively for a long time. The identification of suitable targets, thus, depends on better understanding of the signaling pathways involved in the initiation and maintenance of inflammation. The availability of target validation technology, such as targeted mutagenesis in mice, gene silencing mediated by small interfering RNA and protein expression profiling in this context is of utmost importance. Here, we will focus on the latter two technologies.
Export Options
About this article
Cite this article as:
Clarissa Gust Tatjana and Bonin v. Arne, Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (1) . https://dx.doi.org/10.2174/187152307779939723
DOI https://dx.doi.org/10.2174/187152307779939723 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [ Hot Topic:Immunomodulation in Helminth Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience NPY and Receptors in Immune and Inflammatory Diseases
Current Topics in Medicinal Chemistry Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Bronchoalveolar Lavage in Systemic Sclerosis Patients: A Systematic Review
Current Rheumatology Reviews Therapeutic Strategies to Reverse Local Bone Loss in Erosive Arthritis
Current Rheumatology Reviews Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Bronchiolar Disorders In Childhood
Current Pediatric Reviews FDG-PET/CT in Rheumatoid Arthritis: A Review
Current Molecular Imaging (Discontinued) The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19
Recent Patents on Anti-Infective Drug Discovery Editorial The Role of Mesenchymal Stem Cells in Bone Regeneration: Underlying Mechanisms and Systemic Regulatory Factors
Current Stem Cell Research & Therapy Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Current Pharmaceutical Design Functions of the Third Intracellular Loop of the Human Melanocortin-3 Receptor
Current Pharmaceutical Design The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews The Role of Synovial Fibroblasts in Mediating Joint Destruction in Rheumatoid Arthritis
Current Pharmaceutical Design Polyunsaturated Fatty Acids in Emerging Psychosis
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Psoriasis Therapy
Current Drug Targets - Inflammation & Allergy Role and Function of Adenosine and its Receptors in Inflammation, Neuroinflammation, IBS, Autoimmune Inflammatory Disorders, Rheumatoid Arthritis and Psoriasis
Current Pharmaceutical Design